Replies to post #2543 on Ocera Therapeutics fka OCRX

[biotech_researcher]

I think OCRX has a fair—but not great—chance of persuading the FDA to endorse advancing OCR-002 to phase-3,

I agree and that is why I exited my position on the pop a month ago on the STOP-HE data update. Fair chance doesn't cut it anymore for me..

Buyout might be possible..

[DewDiligence]

Transcript of OCRX 1Q17 CC:

https://finance.yahoo.com/news/edited-transcript-ocrx-earnings-conference-143035349.html

[DewDiligence]

KOL webcast on 6/2/17:

https://globenewswire.com/news-release/2017/05/26/999321/0/en/Ocera-Therapeutics-to-Host-KOL-Conference-Call-on-Hepatic-Encephalopathy-and-Other-Complications-of-Liver-Disease-on-Friday-June-2.html

[DewDiligence]

OCRX starts phase-2a trial for oral formulation of OCR-002 in cirrhotic patients—results expected by year-end:

#msg-131820624